Cytek Biosciences, Inc. CTKB Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$66.54M— | —— | —— | $2.48M— | ||
| $7.58M+5.1% | $7.21M+19.2% | $6.05M+143% | $2.49M+101% | ||
| $24.59M-8.4% | $26.85M+21.8% | $22.05M+32.9% | $16.6M+152% | ||
| $33.56M+1,263% | -$2.89M— | $0— | $0— | ||
| -$415K-655% | -$55K-686% | -$7K— | —— | ||
| $413K— | —— | $269K— | —— | ||
| —— | $5.43M-28.5% | $7.6M-61.5% | $19.74M+59.7% | ||
| —— | -$14.76M-244% | -$4.29M— | —— | ||
| —— | —— | -$1.78M— | —— | ||
| $3.97M— | —— | —— | $7.47M-32.0% | ||
| $2.66M-5.4% | $2.81M-72.9% | $10.35M-46.6% | $19.36M+210% | ||
| —— | —— | —— | —— | ||
| $3.6M-3.6% | $3.74M— | —— | $9.41M-6.0% | ||
| $4.4M+34.1% | $3.28M+3.0% | $3.18M+0.5% | $3.17M— | ||
| —— | —— | —— | —— | ||
| -$4.79M-119% | $25.38M— | —— | —— | ||
| $4.08M+15.9% | $3.53M-24.2% | $4.65M-52.3% | $9.75M+123% | ||
| $108K-49.1% | $212K+18.4% | $179K— | —— | ||
| $252K-12.5% | $288K— | —— | $0— | ||
| —— | -$85M— | —— | -$55.91M-166% | ||
| —— | $21.62M— | —— | —— | ||
| $5.58M+33.4% | $4.18M— | $0-100% | $2.98M— | ||
| $4.75M+752% | $557K-1.4% | $565K+1,030% | $50K— | ||
| $325K-68.0% | $1.02M-30.9% | $1.47M+21.9% | $1.2M+87.5% | ||
| —— | -$15.82M+62.2% | -$41.81M-858% | $5.51M-97.4% | ||
| $109K— | —— | —— | -$2.62M-300% | ||
| —— | -$68.89M— | —— | -$65.12M-133% | ||
| $2.16M-43.6% | $3.83M-27.8% | $5.31M-48.9% | $10.39M+263% | ||
| $0— | $0-100% | $320K— | $0— | ||
| $3.6M-3.6% | $3.74M— | —— | $9.41M-6.0% | ||
| -$1.13M-2.5% | -$1.11M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $2.66M-5.4% | $2.81M-72.9% | $10.35M-46.6% | $19.36M+210% | ||
| -$328K+95.4% | -$7.19M-556% | $1.58M-27.6% | $2.18M+28.9% | ||
| $1.7M+3.5% | $1.65M+12.1% | $1.47M+94.2% | $756K— | ||
| —— | -$5.21M+21.8% | -$6.66M-8,551% | -$77K— | ||
| $4.4M+34.1% | $3.28M+3.0% | $3.18M+0.5% | $3.17M— | ||
| —— | —— | —— | —— | ||
| $413K— | —— | $269K— | —— | ||
| $108K-49.1% | $212K+18.4% | $179K— | —— | ||
| $252K-12.5% | $288K— | —— | $0— | ||
| $670K+20.9% | $554K+32.2% | $419K+100% | $209K— | ||
| $4.75M+752% | $557K-1.4% | $565K+1,030% | $50K— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $0-100% | $510K— | —— | ||
| —— | $2.72M— | —— | $0— | ||
| $2.16M-43.6% | $3.83M-27.8% | $5.31M-48.9% | $10.39M+263% | ||
| —— | —— | —— | —— | ||
| -$8.77M-140% | $21.85M+3,352% | $633K+103% | -$21.98M-8,363% | ||
| -$8.77M-140% | $21.85M+3,352% | $633K+103% | -$21.98M-8,363% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cytek Biosciences, Inc. generate?
- Cytek Biosciences, Inc. (CTKB) generated -$7.4M in operating cash flow over the trailing twelve months.
- What is Cytek Biosciences, Inc.'s free cash flow?
- After $5.4M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$12.7M over the trailing twelve months, down 172.6% year over year.
- Where does Cytek Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
